# Tolerability and Bioavailability of the P144 Peptide Inhibitor of TGF-β1 After Topical Administration in Healthy Volunteers

> **NCT00656825** · PHASE1 · COMPLETED · sponsor: **ISDIN** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** P144 cream
- **DRUG:** P144 cream
- **DRUG:** P144 cream
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00656825
- **Lead sponsor:** ISDIN
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2008-11-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00656825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00656825, "Tolerability and Bioavailability of the P144 Peptide Inhibitor of TGF-β1 After Topical Administration in Healthy Volunteers". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00656825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*